Although the molecular expression of CD34 and BRAFV600E mutation could frequently and exclusively occur in GG with epilepsy, their clinical and pathological features were not yet well defined, as well as the prediction of long-term seizure outcome and tumor recurrence or progression (Blümcke et al., 1999; Dahiya et al., 2013; Zhang et al., 2017; Giulioni et al., 2019; Xing et al., 2021). This evidence concerns the gene CD34 and neoplasm.